journal
https://read.qxmd.com/read/37361909/therapy-for-hiv-associated-cryptococcal-meningitis-a-case-report-demonstrating-a-new-treatment-approach-emphasizing-updated-treatment-guidelines
#1
JOURNAL ARTICLE
David M Hachey, Brian R Wood, Martha Buitrago, Anushka Burde
Cryptococcal meningitis (CM) remains a significant global health burden, especially for persons living with HIV. Despite effective antiretroviral and antifungal therapy, mortality rates are still approximately 70% in low- and middle-income countries and 20-30% in high-income countries. Central nervous system symptoms range from mild to severe, depending on burden of disease, and prompt and appropriate therapy is critical to reducing mortality. Treatment consists of three phases: induction, consolidation, and maintenance...
June 12, 2023: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36811119/clozapine-is-the-approved-option-in-treatment-resistant-schizophrenia-and-requires-careful-management
#2
REVIEW
Caroline Fenton, Connie Kang
Clozapine is the only agent approved for treatment-resistant schizophrenia, but is underprescribed. Its adverse drug event (ADE) profile and patient monitoring requirements can discourage its use, but the benefits of clozapine generally outweigh its risks, as most ADEs are manageable. Careful patient assessment, gradual titration, minimum effective dosages, therapeutic drug monitoring and checks of neutrophils, cardiac enzymes and ADE symptoms are recommended. Neutropenia is common but does not necessarily warrant permanent clozapine cessation...
2023: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36532315/nirmatrelvir-plus-ritonavir-in-covid-19-a-profile-of-its-use
#3
REVIEW
Hannah A Blair
UNLABELLED: Oral nirmatrelvir plus ritonavir (Paxlovid™ ) is an effective treatment option for coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nirmatrelvir inhibits the main protease of SARS-CoV-2, with ritonavir acting as a pharmacokinetic booster. In the phase II/III EPIC-HR trial, nirmatrelvir plus ritonavir reduced the risk of progression to severe COVID-19 in symptomatic, unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression to severe disease...
2023: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36532316/antidepressants-with-anti-inflammatory-properties-may-be-useful-in-long-covid-depression
#4
REVIEW
Caroline Fenton, Arnold Lee
Long COVID, which is characterised by the presence of persistent symptoms following a COVID infection, may also cause long COVID depression (LCD). Although the risk factors for LCD are not directly characterised, prior mental health visits were associated with an increased risk for long COVID, whereas antidepressant use was not. Current evidence suggests that pro-inflammatory factors in the brain are linked to LCD, thus anti-inflammatory agents may be useful in mitigating LCD. Limited evidence suggests that selective serotonin reuptake inhibitors may also be effective in the treatment of LCD...
December 12, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36440380/the-role-of-professional-socialisation-in-reducing-drug-related-problems-during-covid-19-a-new-insight-for-future-pandemics
#5
JOURNAL ARTICLE
Ahmad Z Al Meslamani
No abstract text is available yet for this article.
November 18, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36405931/mrna-covid-19-vaccines-are-well-tolerated-and-myopericarditis-is-a-rare-adverse-event-following-immunisation
#6
REVIEW
Caroline Fenton, Arnold Lee
mRNA vaccines are considered to be important tools for the management of the COVID-19 pandemic. Although mRNA COVID-19 vaccines are well tolerated in most recipients, post-marketing data have highlighted an association between myocarditis and mRNA vaccines. Post-vaccine myocarditis (PVM) is most commonly reported in male adolescents receiving the second dose of an mRNA vaccine. However, the incidence of PVM is low and the risk of myocarditis should be kept in perspective. Cases of PVM are mostly mild in severity, and may be managed using existing myocarditis guidelines...
November 15, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35967543/first-reports-of-adverse-drug-reactions-and-drug-interactions
#7
(no author information available yet)
No abstract text is available yet for this article.
August 6, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35789563/plasma-lipid-profile-a-predictive-marker-of-disease-severity-among-covid-19-patients-an-opportunity-for-low-income-countries
#8
JOURNAL ARTICLE
Yasser O Mosaad, Mohamed A Baraka, Ahmed E Abou Warda, Hayam Ateyya, Mohammed A Hussein, Sayed Gaber
Objective: This study aimed to assess the correlation between body mass index (BMI) and plasma lipid profile levels in mild and severe COVID-19 patients. Method: This was a prospective, observational, cohort study, conducted in a medical referral center specializing in management of COVID-19 cases. Patients were divided into two groups according to infection severity (mild and severe). Blood samples were obtained from all patients who tested positive to a PCR test for measuring biochemical and inflammatory markers such as lactate dehydrogenase, ferritin, C-reactive protein, and d-dimer, as well as lipid profile, including total cholesterol, triacylglycerols, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), which were analyzed and compared between the two groups...
June 27, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35600797/first-reports-of-adverse-drug-reactions
#9
(no author information available yet)
No abstract text is available yet for this article.
May 16, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35340931/building-evidence-for-improving-vaccine-adoption-and-uptake-of-childhood-vaccinations-in-low-and-middle-income-countries-a-systematic-review
#10
REVIEW
F Aslam, I Ali, Z Babar, Y Yang
Vaccine coverage for children is an important indicator of the performance of national health and immunization systems. Most of the existing literature has targeted mothers' low educational level, living in underserved districts and/or remote rural areas and economic poverty that are correlated with low immunization coverage but the supply- and demand-side constraints to immunization in low- and middle- income countries (LMICs) are not well understood. The reliability of claimed administrative immunization coverage in these contexts is questionable...
March 19, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35250258/emerging-small-molecule-antivirals-may-fit-neatly-into-covid-19-treatment
#11
REVIEW
Caroline Fenton, Susan J Keam
Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although most are not well established; among these are several small molecule antiviral agents. Intravenous remdesivir is an established treatment worldwide for inpatients and in some countries is also available for use in non-hospitalised high risk patients to prevent progression to severe disease and hospitalization. Oral molnupiravir and oral nirmatrelvir-ritonavir are also available in several countries to prevent progression to severe disease and hospitalization for high-risk outpatients...
February 28, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35194372/peak-months-of-pandemic-s-first-wave-in-india-a-cross-sectional-assessment-of-knowledge-attitudes-and-practice-towards-covid-19-among-internet-savvy-individuals
#12
JOURNAL ARTICLE
Jeevitha Marudachalam, Oviyha Ravichandhiran, Kameswaran Ramalingam, Sambathkumar Ramanathan, Sirajudeen Mahaboob, Habeeb Ibrahim Abdul Razack
Background: A successful pandemic response in populated geographies and resource-limited settings like India relies on informed decision making. Knowledge, attitudes, and practices (KAP) studies performed during these times are crucial to illustrate how well a community adopts prevention strategies. Objective: The present study, conducted during the peak months of the first wave of the COVID-19 pandemic, aimed at assessing the KAP levels of internet-savvy Indians...
February 10, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35095267/adverse-drug-reactions-from-two-covid-19-vaccines-reported-in-saudi-arabia
#13
JOURNAL ARTICLE
Amjad Alfaleh, Abdullah Alkattan, Nashwa Radwan, Mona Elzohri, Abrar Alzaher, Mona Ibrahim, Eman Alsalameen, Amani Alsultan, Dina Alhabib, Alanood Alshelwah, Nagla Mahmoud, Khlood Sagor, Khaled Alabdulkareem
Background: Several reports have been published about the impact of coronavirus disease 2019 (COVID-19) vaccines on human health, and each vaccine has a different safety and efficacy profile. The aim of this study was to reveal the nature and classification of reported adverse drug reactions (ADRs) of the two COVID-19 vaccines (tozinameran and ChAdOx1) among citizens and residents living in Saudi Arabia, and show possible differences between the two vaccines and the differences between each batch on the health of populations...
January 22, 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36439641/acknowledgement-to-referees
#14
(no author information available yet)
No abstract text is available yet for this article.
2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36276914/first-reports-of-adverse-drug-reactions-and-drug-interactions
#15
(no author information available yet)
No abstract text is available yet for this article.
2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36093265/rts-s-as01-malaria-vaccine-mosquirix-%C3%A2-a-profile-of-its-use
#16
REVIEW
Yahiya Y Syed
RTS,S/AS01 (Mosquirix® ) is a vaccine against malaria caused by Plasmodium falciparum . In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy against clinical malaria, severe malaria and malaria hospitalization, with an acceptable safety and tolerability profile, in children aged 6 weeks to 17 months; the vaccine efficacy was greater in children than in infants and waned over time. In another phase 3 trial, RTS,S/AS01 was noninferior to seasonal malaria chemoprevention in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of P...
2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/36068824/design-and-implementation-of-an-online-tool-for-managing-the-availability-of-high-cost-perishable-medicines
#17
JOURNAL ARTICLE
Myriam Gallego Galisteo, Javier Romero Puerto, Maria José Martínez Bautista, Jorge Díaz Navarro, Rosa Seisdedos Elcuaz, Juan Gallego Galisteo, Alberto Villa Rubio, María Del Carmen Jiménez de Juan, Ana Ganfornina Andrades, Marcelo Domínguez Cantero, José Carlos Roldán Morales, Jaime Cordero Ramos, Alfonso Sánchez García, Carlos Núñez Ortiz, José Ramón Ávila Álvarez
Introduction: Due to their impact on healthcare systems, the sustainability and optimization of high-cost drugs is an issue of concern for several countries. Different strategies have been implemented such as centralized purchasing to optimize budgetary resources. However, there is still a need for a mechanism to optimize these drugs further. Methods: We conducted this prospective multicenter intervention study in five hospitals in the Andalusian Public Health System of Cádiz (Spain) between July 2019 and September 2021...
2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35755971/antibiotic-prescribing-patterns-for-acute-respiratory-infections-in-a-free-clinic-network-a-pooled-cross-sectional-study
#18
JOURNAL ARTICLE
Anshul Daga, Oliver T Nguyen, Elijah Moothedan, Daniel M Czyz, Aashi Faldu, Taylor Ham, Arshia Goyal, Kartik Motwani, David B Feller
In the United States, overprescribing of antibiotics for viral respiratory infections and antimicrobial resistance continue to be public health concerns. To date, no literature has focused on antibiotic prescribing patterns from free clinics. To address this gap, we used patient-level data from a student-run free clinic network of four primary care clinics to assess factors associated with inappropriate antibiotic prescribing for viral respiratory infections. Treatment plans were deemed inappropriate if any type of antibiotic was prescribed...
January 2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35313703/evaluation-of-three-barrier-type-closed-system-transfer-devices-using-the-2015-niosh-vapor-containment-performance-draft-protocol
#19
JOURNAL ARTICLE
Andrew Szkiladz, Shawn Hegner
Background: Closed System Transfer Devices (CSTD) have been developed to reduce healthcare worker exposure to hazardous drugs during medication handling. To evaluate CSTD performance in preventing the escape of drug vapors, the National Institute for Occupational Safety and Health (NIOSH) developed a 2015 draft testing protocol incorporating two compounding tasks utilizing 70% isopropyl alcohol (IPA) as a medication surrogate. Purpose: The objective of this study was to evaluate the performance of three CSTDs (Chemolock [ICU Medical Inc...
2022: Drugs & Therapy Perspectives
https://read.qxmd.com/read/35002218/first-reports-of-adverse-drug-reactions
#20
(no author information available yet)
No abstract text is available yet for this article.
2022: Drugs & Therapy Perspectives
journal
journal
49726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.